Physician profile
Muhammad A Ali
NPI 1306826250
$7,767.63
in general payments reported to CMS, 2019-2025
58 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $341 · 2021: $324 · 2022: $646 · 2023: $1,305 · 2024: $1,631 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,101 · Education: $61.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,101.45 |
| Education | $61.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,059.67 | 2019-2025 | |
| Janssen Biotech, INC. | $752.97 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Merck Sharp & Dohme LLC | $682.79 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $587.19 | 2019-2025 | Imfinzi, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $389.95 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $338.86 | 2019-2025 | Polivy, Columvi, Lunsumio |
| Daiichi Sankyo INC. | $321.76 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $321.44 | 2022-2025 | Venclexta |
| Pfizer INC. | $312.21 | 2019-2025 | |
| Incyte Corporation | $271.27 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Astellas Pharma US INC | $251.21 | 2023-2025 | Vyloy, Xospata, Xtandi |
| Genzyme Corporation | $231.91 | 2019-2025 | |
| Array Biopharma INC | $163.06 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Celgene Corporation | $130.42 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $111.90 | 2019-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $96.75 | 2021-2025 | Trodelvy |
| Beone Medicines USA, INC. | $96.11 | 2025 | Tevimbra, Brukinsa |
| Exelixis INC. | $95.41 | 2019-2024 | Cabometyx |
| Amgen INC. | $93.91 | 2019-2023 | Kyprolis |
| Aveo Pharmaceuticals, INC. | $93.26 | 2022-2025 | Fotivda |
| Eisai INC. | $89.44 | 2019-2025 | |
| Seagen INC. | $88.74 | 2019-2023 | Tukysa, Padcev |
| Regeneron Healthcare Solutions, INC. | $82.84 | 2022-2025 | Lynozyfic, Libtayo |
| Glaxosmithkline, LLC. | $79.13 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Emd Serono, INC. | $69.20 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.25 | 2019-2024 | Iclusig |
| Lilly USA, LLC | $61.80 | 2019-2025 | Verzenio, Jaypirca, Inluriyo |
| Mirati Therapeutics, INC. | $58.82 | 2023-2024 | Krazati |
| Blueprint Medicines Corporation | $55.30 | 2021-2025 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $54.71 | 2019-2023 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $53.61 | 2019-2023 | Imbruvica |
| Janssen Pharmaceuticals, INC | $49.46 | 2019-2023 | Xarelto |
| Beigene USA, INC. | $49.02 | 2024 | Brukinsa |
| Tersera Therapeutics LLC | $47.66 | 2024-2025 | Zoladex |
| Rigel Pharmaceuticals, INC. | $44.77 | 2020-2024 | Tavalisse, Rezlidhia |
| Foundation Medicine, INC. | $44.31 | 2019 | |
| Tempus Ai, INC | $37.39 | 2024-2025 | Xt Cdx |
| Syndax Pharmaceuticals, INC. | $34.73 | 2025 | |
| Servier Pharmaceuticals LLC | $32.55 | 2022-2025 | |
| Sobi, INC | $31.79 | 2024 | |
| Verastem, INC. | $30.38 | 2019 | |
| Clovis Oncology, INC. | $27.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.25 | 2024 | Gilotrif |
| Nuvation Bio INC. | $21.79 | 2025 | Ibtrozi |
| Kyowa Kirin, INC. | $20.39 | 2024 | Poteligeo |
| Puma Biotechnology, INC. | $18.49 | 2019 | |
| Adc Therapeutics America, INC. | $18.30 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.99 | 2025 | |
| Deciphera Pharmaceuticals INC. | $16.94 | 2024 | Qinlock |
| Fennec Pharmaceuticals, INC. | $14.24 | 2024 | Pedmark |
| Taiho Oncology, INC. | $13.99 | 2024 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.